Cerebrolysin

DB16599Investigational

Cerebrolysin is a proteolytic protein indicated in the treatment of cerebrovascular disorders. A medication used to treat blood flow disorders in the brain.

Mechanism: Pharmacologically active on Cyclin-dependent kinase 5 and Glycogen synthase kinase-3 beta
Curator reviewed
Also known as: Cerebrolyzin
Code names: FPE 1070 · FPF-1070

Resolves to

Compound

UNII37KZM6S21GCAS12656-61-0

Targets

Q00535CDK5P49841GSK3B

What you can answer from here — as of September 05, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

40Clinical trialsPhase, status and sponsor resolved per trial

4Structured indicationsCondition, population, route and combination as fields, not prose

3ContraindicationsEach with its own population and attribute set

3Marketed productsAcross 1 country and 1 labeller

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cerebrolysin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account